# Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

> **NCT00006226** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (estimated)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** thalidomide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00006226
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006226, "Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00006226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*